中枢神经系统桥接放疗在侵袭性B细胞淋巴瘤CAR-T治疗前实现快速减瘤
该研究纳入接受商业CAR-T治疗前进行中枢神经系统桥接放疗(CNS-BRT)的中枢神经系统淋巴瘤(CNSL)患者,评估其减瘤效果与安全性。12例患者中10例CNSL、2例硬膜外病变,CNS-BRT后病灶平均缩小74.0%(95%CI 62.0-86.0,P=.014),最佳中枢反应包括8例完全缓解、1例部分缓解、1例进展,3例出现放疗野外中枢复发;1例发生≥3级细胞因子释放综合征,3例发生≥3级免疫效应细胞相关神经毒性综合征。初步数据提示CNS-BRT可实现快速减瘤并具有有利的中枢反应和安全性,支持进一步研究。
要点
- CNS-BRT从基线至CAR-T输注前实现病灶平均缩小74.0%(95%CI 62.0-86.0,P=.014),中位距放疗完成12天。
- 10例CNSL最佳中枢反应为8例完全缓解、1例部分缓解、1例进展。
- 12例中1例发生≥3级细胞因子释放综合征,3例发生≥3级免疫效应细胞相关神经毒性综合征。
核心结论
- 初步数据提示CNS-BRT可实现快速减瘤,并与有利的中枢反应和安全性相关。
- 这些数据支持进一步研究BRT作为CNSL CAR-T治疗的桥接方式。
研究设计与样本
- 研究纳入接受商业CAR-T治疗前进行CNS-BRT的非霍奇金B细胞淋巴瘤CNSL患者。
- 共12例患者接受CNS-BRT,其中10例为CNSL(9例继发性、1例原发性),2例为硬膜外病变(仅评估毒性)。
- 存活者中位随访时间为11.8个月(四分位距8.5-21.9)。
- CNS-BRT的减瘤效果按CAR-T前病灶大小变化计算。
主要发现
- 全部10例CNSL患者在CNS-BRT时均为进展性疾病。
- CNS-BRT从基线实现病灶平均缩小74.0%(95%CI 62.0-86.0,P=.014),中位距BRT完成12天且发生在CAR-T输注前。
- 最佳中枢反应包括8例完全缓解、1例部分缓解和1例进展性疾病。
- 3例患者出现BRT野外中枢复发。
- 12例中1例发生≥3级细胞因子释放综合征,3例发生≥3级免疫效应细胞相关神经毒性综合征。
临床怎么用
- 原文结论支持进一步研究BRT作为CNSL CAR-T治疗的桥接方式,未据此给出临床推荐。
局限性
- 原文结论称初步数据提示CNS-BRT可实现快速减瘤并与有利的中枢反应和安全性相关,并支持进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T-cell therapy (CART) for central nervous system lymphoma (CNSL) is a promising strategy, yet responses are frequently not durable. Bridging radiotherapy (BRT) is used for extracranial lymphoma in which it can improve CART outcomes through cytoreduction of high-risk lesions. We hypothesized that BRT would achieve similar, significant cytoreduction before CART for CNSL (CNS-BRT). We identified patients with CNSL with non-Hodgkin B-cell lymphoma who received CNS-BRT before commercial CART. Cytoreduction from CNS-BRT was calculated as change in lesion size before CART. Twelve patients received CNS-BRT, and the median follow-up among survivors is 11.8 months (interquartile range, 8.5-21.9). Ten patients had CNSL (9 secondary, 1 primary) and 2 patients had epidural disease (evaluable for toxicity). All 10 patients with CNSL had progressive disease at the time of CNS-BRT. Of 12 patients, 1 experienced grade ≥3 cytokine release syndrome, and 3 of 12 patients experienced grade ≥3 immune effector cell-associated neurotoxicity syndrome. CNS-BRT achieved a 74.0% (95% confidence interval, 62.0-86.0) mean reduction in lesion size from baseline (P = .014) at a median of 12 days from BRT completion and before CART infusion. Best CNS response included 8 complete responses, 1 partial response, and 1 progressive disease. Three patients experienced CNS relapse outside the BRT field. Preliminary data suggest CNS-BRT achieves rapid cytoreduction and is associated with a favorable CNS response and safety profile. These data support further study of BRT as a bridging modality for CNSL CART.
引用
- Cederquist GY, Schefflein J, Devlin SM, et al. CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas. Blood Adv. 2024. PMID: 38861344. doi:10.1182/bloodadvances.2024013393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。